NLRP3 and CINCA syndrome: Additionally, ChoKα inhibition has therapeutic effects in three models of chronic syndromes associated with cryopyrin (CAPS): Muckle–Wells syndrome (MWS), familial cold autoinflammatory syndrome (FCAS) and neonatal-onset multisystem inflammatory disease (NOMID).